Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial - Summary - MDSpire

Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial

  • By

  • M Tobiasson

  • I Dybedahl

  • M S Holm

  • M Karimi

  • L Brandefors

  • H Garelius

  • M Grövdal

  • I Högh-Dufva

  • K Grønbæk

  • M Jansson

  • C Marcher

  • L Nilsson

  • A O Kittang

  • A Porwit

  • L Saft

  • L Möllgård

  • E Hellström-Lindberg

  • March 7, 2014

  • 0 min

Share

Objective:

To study the efficacy of azacitidine (Aza) in inducing transfusion independence (TI) in previously transfusion-dependent (TD) patients with lower-risk myelodysplastic syndromes (MDS) who are resistant to growth factors, specifically erythropoiesis-stimulating agents (ESA).

Key Findings:
  • Overall efficacy of Aza was limited with considerable toxicity, and only a minority of patients achieved transfusion independence.
  • A high frequency of recurrent gene mutations, particularly in splice factor genes and epigenetic regulators, was observed, indicating potential targets for future therapies.
Interpretation:

The study suggests that Aza may not be effective in inducing TI in TD, ESA-resistant patients with lower-risk MDS, highlighting the need for alternative treatment strategies and further research to explore these options.

Limitations:
  • Small sample size of 30 patients may limit generalizability, particularly in diverse populations.
  • Lack of a control group for comparison restricts the ability to draw definitive conclusions about the efficacy of Aza.
Conclusion:

The trial indicates limited clinical efficacy of azacitidine in the targeted patient population, necessitating further research to identify effective treatments for this group.

Original Source(s)

Limited clinical efficacy of azacitidine in transfusion-dependent, growth factor-resistant, low- and Int-1-risk MDS: Results from the nordic NMDSG08A phase II trial

  • by M Tobiasson, I Dybedahl, M S Holm, M Karimi, L Brandefors, H Garelius, M Grövdal, I Högh-Dufva, K Grønbæk, M Jansson, C Marcher, L Nilsson, A O Kittang, A Porwit, L Saft, L Möllgård, E Hellström-Lindberg

  • March 7, 2014

Related Content

Clinical Reasoning in Practice: Implementing High-Value Care When Data Discrepancies Arise

Smoldering Waldenström macroglobulinemia coexisting with myelodysplastic syndrome: a rare case report and literature review

Hematological abnormalities in clinically diagnosed non-alcoholic steatohepatitis: prevalence, clinical correlates, and fibrosis risk in a case–control study from Qatar